Angiodynamics, Inc. · NASDAQ:ANGO

Angiodynamics — Q2 FY2020 Earnings Presentation

9 slides from Angiodynamics's earnings presentation, Jan 7, 2020

  1. Slide 1: AngioDynamics Second Quarter 2020 Earnings Presentation

    AngioDynamics Second Quarter 2020 Earnings PresentationJanuary 7, 2020

  2. Slide 2: Notice Regarding Forward-Looking Statements

    Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strateg

  3. Slide 3: Second Quarter FY2020 Highlights

    Second Quarter FY2020 Highlights Corporate Developments NanoKnife DIRECT study: 13 sites have IRB approval to begin patient enrollment; anticipate approximately 5 more site approvals by end of fiscal year 2020.Received Category III CPT physician billing codes for irreversible electroporation.Announc

  4. Slide 4: Second Quarter FY2020 Results (unaudited)

    Second Quarter FY2020 Results (unaudited) $ in thousands (except per share data) FY2020Q2 Results FY2019Q2 Results Change FY2020YTD Results FY2019YTD Results Change Revenue Vascular Interventions and Therapies Vascular Access Oncology United States International $70,00331,15022,78416,06955,55514,448

  5. Slide 5: FY2020 Guidance

    FY2020 Guidance RevenueAdjusted EPS Gross Margin Current Guidance (Unchanged)$280m - $286m$0.10 - $0.1558% - 59%

  6. Slide 6: GAAP to Non-GAAP Reconciliation

    GAAP to Non-GAAP Reconciliation

  7. Slide 7: Reconciliation of GAAP to Non-GAAP Net Income and EPS

    Reconciliation of GAAP to Non-GAAP Net Income and EPS Amounts in thousands Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items.Deferred financing fees related to the old credit

  8. Slide 8: Reconciliation of Net Income to Adjusted EBITDA

    Reconciliation of Net Income Adjusted EBITDA Amounts in thousands

  9. Slide 9: Growth through Focus, Execution, Accountability

    Growth through Focus Execution Accountability

AngioDynamics — Q2 FY2020 Earnings Presentation on 6ix